Skip to Content

DB289 Approval Status

FDA Approved: No
Brand name: DB289
Generic name: pafuramidine
Company: Immtech Pharmaceuticals, Inc.
Treatment for: Pneumocystis Pneumonia

DB289 (pafuramidine) is an investigational drug intended for use in the treatment of pneumocystis pneumonia.

In November 2006, Immtech Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted orphan drug designation for pafuramidine (DB289) to treat Pneumocystis jiroveci pneumonia (PCP), a common life-threatening opportunistic infection in HIV/AIDS and other immunosuppressed patients.

Development Status and FDA Approval Process for DB289

DateArticle
Nov 21, 2006US FDA Grants Immtech's Oral Drug Candidate Pafuramidine (DB289) Orphan Drug Status for Treatment of PCP

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide